GLS · Gelesis Holdings Inc

Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its non-systemic superabsorbent hydrogels are the first and only made entirely from naturally derived building blocks, and they are inspired by the composition (i.e., water & cellulose) and mechanical properties (e.g., elasticity or firmness) of raw vegetables. They are conveniently administered in capsules to create a much larger volume of small, non-aggregating hydrogel pieces that become an integrated part of the meals, and act locally in the digestive system. Its portfolio includes Plenity®, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.

501 Boylston Street, Suite 6102, MA, 02116, US
Research and Development in Biotechnology
Professional, Scientific, and Technical Services

Market Cap

N/A

52 Wk Range

N/A - N/A

Previous Close

$0.16

Open

N/A

Volume

N/A

Day Range

N/A - N/A

Enterprise Value

N/A

Cash

N/A

Avg Qtr Burn

N/A

Insider Ownership

52.70%

Institutional Own.

29.38%

Qtr Updated

Jun 30th 2024